Media Mentions Archive
Both the work and the people associated with the Johns Hopkins Drug Access and Affordability Initiative (JHDAAI) make frequent appearances in the media.
View the archived "Media Mentions" involving the JHDAAI project team below.
2022 Media Mentions
Here's one good way to lower the cost of insulin
Insulin has been making life better for people with diabetes since it first saved the life of a Canadian teenager in 1922. As the ensuing century passed, however, the drug also became a poster child for the dysfunctionality of America’s drug-pricing system. Gerard Anderson is quoted.
Washington Post | March 10, 2022
What's in a name? When it comes to prescription drugs, a lot, experts say
Although drug brand names seen in television advertisements, magazine ads and elsewhere may seem bizarre, typically there's a method behind the madness, experts said. Caleb Alexander is quoted.
UPI Health News | January 21, 2022
Medicare to restrict Aducanumab coverage
The Centers for Medicare & Medicaid Services (CMS) has announced a preliminary National Coverage Determination restricting Medicare coverage of the Alzheimer’s disease drug aducanumab-avwa (Aduhelm, Biogen) to patients who are participating in approved placebo-controlled clinical trials. Caleb Alexander is quoted.
Pharmacy Practice News | January 13, 2022
2021 Media Mentions
Med cost makes 12 million Americans miss their medications every year
The latest figures from the Organization for Economic Cooperation and Development indicate that Americans spend more than $1,100 on prescription drugs a year. The average person pays more than anyone else in a developed country. Gerard Anderson is quoted.
The NU Herald | December 10, 2021
Medicare negotiating drug prices could be the game changer Americans need
All hopes for decreased drug pricing seemed lost last week, after President Biden dropped all efforts to do so in his social spending bill. House Democrats successfully reinserted a plan to lower drug costs—albeit a pared-back version of the original. Mariana Socal is quoted.
Fortune | November 5, 2021
Despite restraints, democrats' drug pricing plan could still aid consumers
The Medicare prescription drug pricing plan Democrats unveiled this week is not nearly as ambitious as many lawmakers sought, but they and drug policy experts say the provisions open the door to reforms that could have dramatic effects. Gerard Anderson is quoted.
News-Medical Life Sciences | November 5, 2021
Democrats reach deal aimed at cutting drug prices for seniors
As part of President Biden’s yet-to-be-settled social-spending plan, Democrats in Congress have reached a deal to lower the cost of prescription drugs for older Americans. The agreement would cap out-of-pocket spending for seniors at $2,000 a year and, for the first time, give Medicare the power to negotiate prices directly with drugmakers. Mariana Socal is quoted.
Marketplace | November 3, 2021
Neustatter: Spoiling the ship for a ha'p'orth of tar
A “Ha’p’orth of Tar” and Profitability -- this quaint old expression means spoiling the whole project for stinting on that last little bit of “tar,” which in this case was his medication. Gerard Anderson is quoted.
The Free Lance-Star | October 30, 2021
America's substance use crisis has spiraled during the pandemic
The forced isolation, disruption to treatment and resource demands created by the pandemic have set America back in its efforts to end the opioid epidemic. Caleb Alexander is quoted.
Axios | October 30, 2021
Federal pharma ingredient stockpile is under construction in Virginia
Some basic medications are in short supply in the United States. Part of the problem is that most of the ingredients for generic and over-the-counter drugs produced in the U.S. are imported, mainly from China and India. And those countries cut their exports during the pandemic. One possible solution? A new government stockpile of the ingredients used to make these medicines. Mariana Socal is quoted.
Marketplace | October 19, 2021
The FDA’s accelerated approval process: When drugs are cleared for sale based on limited evidence
Accelerated approval is an important topic for journalists to consider in their ongoing coverage of drug costs in America. This article explains how the process works -- including examples of successes and controversies. Plus: 5 reporting tips. Caleb Alexander is quoted.
The Journalist's Resource | October 18, 2021
Pfizer loses legal battle with big implications for drug pricing
A federal court has rejected Pfizer’s claims against the government in a case with major implications for drug pricing. Ge Bai is quoted.
MarketWatch | October 1, 2021
The Price We Pay: Why Is Medication So Expensive?
Americans spend twice as much on medical care as people in other wealthy countries, and one of the reasons is the high prices of our prescription drugs. We pay, on average, 2 1/2 times for the same medicines. Many experts say the problem is American brand name drugs — not all drugs. And the drug companies aren’t the only ones who benefit. Ge Bai is quoted.
WAFE / The Takeaway | September 22, 2021
Brand name prescription drugs are costing Americans billions more than generics
Brand name prescription drugs are something many patients simply trust more than their generic (or no-name) alternatives. However, the cost of these drugs is taking a staggering toll on the American health care system. Researchers from Johns Hopkins Bloomberg School of Public Health find that opting for brand name prescriptions over generics costs the Medicare Part D program $1.7 billion more each year. Gerard Anderson and Ge Bai are featured.
Studyfinds | September 8, 2021
Murky math: Senate shelves lower drug prices
The Senate’s release of its bipartisan infrastructure plan signals that lawmakers are poised to throw former President Donald Trump’s belated bid to lower Medicare drug prices under the bus — not to mention trains, bridges, tunnels and broadband connections. Gerard Anderson is quoted.
Galion Inquirer | August 11, 2021
Study: Prescription drug coupons used on fewer than 20% of purchases
Roughly one in five pharmacy purchases include use of a manufacturer coupon, but researchers say the discounts generally only apply new, pricey drugs -- and their availability is often based on those available for rival drugs. So Yeon Kang is featured.
Health News | August 13, 2021
What does the infrastructure bill have to do with Medicare drug rebates?
The massive spending bill is likely to at least delay the so-called Medicare rebate rule released at the end of the Trump administration. Gerard Anderson is quoted.
Benefits Pro | August 5, 2021
Court battle over Pfizer's Medicare copays could result in "gold rush" sales
The Pfizer company paid $24 million to resolve allegations that it had paid kickbacks and allowed Medicare patients to choose their pharmacy out of pocket. Gerard Anderson is quoted.
PV Post | August 2, 2021
FDA panel advisor who panned new Alzheimer's drug speaks out
An outside advisor to the U.S. Food and Drug Administration's review of the controversial Alzheimer's drug Aduhelm is now speaking out, arguing that the approval was based on dodgy science and involved questionable collaboration between regulators and the drug's maker. Caleb Alexander is featured.
Health Day | July 28, 2021
Pfizer court fight could legalize Medicare copays and unleash ‘gold rush’ in sales
Three years ago, pharma giant Pfizer paid $24 million to settle federal allegations that it was paying kickbacks and inflating sales by reimbursing Medicare patients for out-of-pocket medication costs. Gerard Anderson and Michelle Mello are quoted.
Fortune | July 28, 2021
Biohackers could drive insulin price down 98 percent
Diabetes is the seventh-leading cause of death in America. About 463 million people (including 34 million Americans) are diabetic. The cost of insulin continues to surge, so the Open Insulin Project is fighting back by replicating medical-grade insulin that can be made at a lab in your neighborhood. Mariana Socal is quoted.
Big Think | June 29, 2021
2020 Media Mentions
As coronavirus vaccine politics heat up, FDA aims to shore up trust at Johns Hopkins symposium
A day after President Donald Trump promised Americans a coronavirus vaccine “momentarily,” the U.S. Food and Drug Administration released new guidelines Tuesday on what it expects from drug companies as they push for approval of their vaccines. Joshua Sharfstein is quoted.
Baltimore Sun | October 6, 2020
Study: COVID-19 test costs range from one cent to $14,750
The price of COVID-19 testing is all over the place, ranging from one cent to $14,750, according to a study published Tuesday by Johns Hopkins researchers. Ge Bai is quoted.
Houston Chronicle | September 16, 2020
The 1918 flu is still with us: The deadliest pandemic ever is still causing problems today
In the middle of today’s novel coronavirus outbreak, some are turning to the conclusion of past pandemics to discern how and when life might “return to normal.” Jeremy Greene is quoted.
Washington Post | September 3, 2020
Rural hospitals are sinking under COVID-19 financial pressures
As COVID-19 continues to spread, an increasing number of rural communities in the U.S. find themselves without their hospital or on the brink of losing already cash-strapped facilities. Ge Bai is quoted.
WAMU / American University Radio | August 22, 2020
Big pharma spent nearly $250 million lobbying for government's $3 trillion Covid-19 fund package
Congress has approved a package of $3 trillion for Covid-19 relief assistance, making it the largest in US history. Ge Bai is quoted.
MEAWW.com | August 16, 2020
What does a coronavirus test cost? It depends where you go
Covid-19 tests are supposed to be free for anyone who has insurance, but unexpected bills from doctors’ offices and hospitals remain a big concern. Gerard Anderson is quoted.
Bloomberg Law | August 7, 2020
Disconnect between FDA and doctors prescribing hydroxychloroquine
A disconnect appears to have arisen between the Food and Drug Administration and a sizable number of physicians when it comes to prescribing hydroxychloroquine for COVID-19 patients. Caleb Alexander is quoted.
Washington Examiner | August 3, 2020
Disconnect between FDA and doctors prescribing hydroxychloroquine
A disconnect appears to have arisen between the Food and Drug Administration and a sizable number of physicians when it comes to prescribing hydroxychloroquine for COVID-19 patients. Caleb Alexander is quoted.
Washington Examiner | August 3, 2020
Wealthy hospital taps craft breweries for aid to buy masks, gloves
As Inova Health System sought donations in March to buy personal protective equipment for its staff to treat COVID-19, a police officer turned brewer, came to their aid. Gerard Anderson is quoted.
Kaiser Health News | June 16, 2020
Doctors: Remdesivir shows promise in treating coronavirus, questions remain
The U.S. Food and Drug Administration gave emergency approval last month for the drug remdesivir for investigational use in coronavirus patients. Caleb Alexander is quoted.
WBAL TV 11 News | June 5, 2020
Scientists probing whether blood-pressure drugs accelerate coronavirus
Scientists are urgently investigating whether life-saving blood-pressure drugs could also be an important issue behind lots of those that die from the coronavirus. Caleb Alexander is quoted.
Gruntstuff | June 1, 2020
Mexican coronavirus probe finds dozens of unlicensed retirement homes
Officials have discovered dozens of unlicensed retirement homes in northern Mexico, raising fears that so far undetected coronavirus clusters may emerge in the thinly regulated sector. Antonio Trujillo is quoted.
KFGO | May 26, 2020
Coronavirus response: Things the U.S. has got right -- and got wrong
There has been a robust ongoing debate over whether the U.S. was adequately prepared for a pandemic and if the proper steps were taken as the virus began to appear on American soil. Gerard Anderson is quoted.
BBC News | May 13, 2020
Coronavirus pandemic may end socially before it ends medically
According to historians, pandemics have two types of end: the medical, which occurs when incidence and death rates plummet, and the social, when the epidemic of fear of disease decreases. Jeremy Greene is quoted.
PVDN | May 13, 2020
Digital epidemiology: The ethics of using health data in a pandemic
COVID-19 has forced the rapid adoption of digital healthcare – from telehealth to remote monitoring. Digital epidemiology is an area of technological adoption in medicine that can help inform the future of disease surveillance, but there are ethical questions about how this data is used. Michelle Mello is featured.
Health Europa | May 12, 2020
Experts outline strategies for shoring up U.S. drug supplies
Epidemiologist Caleb Alexander co-authors paper urging government officials, pharmaceutical stakeholders to take steps to protect U.S. drug supply chain.
The Hub at Johns Hopkins | May 12, 2020
Five steps U.S. federal, state regulators can take to ensure drug access during COVID-19 pandemic
Federal and state regulators, as well as distributors and pharmacies, must act now to establish anti-stockpiling measures and expand mail-order programs, as well as other policies, to ensure access to needed medications in the United States during the COVID-19 pandemic, according to an editorial published in JAMA. Caleb Alexander is featured.
Healio Rheumatology | April 23, 2020
States all fell short in virus readiness: Experts say hindsight reveals gaps, follies
Today, as states spend billions of dollars in the fight against the coronavirus, that October funding request appears woefully insufficient. Yet, it highlights a stark fact: States were not stocked for a pandemic and have been scrambling to catch up. Gerard Anderson is quoted.
Associated Press | April 24, 2020
The truth about off-label prescribing and coronavirus
One of the most alarming things about COVID-19 is that there are no FDA-approved drugs to fight it. Joshua Sharfstein is quoted.
Yahoo News | April 16, 2020
Should we be worried about a drug shortage?
Dr. Caleb Alexander joins Tommy to talk about the possiblity of a drug shortage due to the coronavirus pandemic.
WWL.com / Radio.com | April 16, 2020
This is insane! Many scientists lament Trump's embrace of risky malaria drugs for coronavirus
When President Donald Trump recently touted the common malaria treatments hydroxychloroquine and chloroquine as potential remedies for coronavirus disease 2019 (COVID-19), he ignited unprecedented demand for the drugs—and set scientists’ teeth on edge. Joshua Sharfstein is quoted.
Science Magazine | March 26, 2020
Coronavirus is far more widespread than official Maryland count suggests. It's no time to ease restrictions, experts say
"Everybody knows it’s a severe undercount,” said Dr. Joshua Sharfstein, former Maryland health secretary and vice dean for public health practice and community engagement at Johns Hopkins Bloomberg School of Public Health. Governors, mayors and other local leaders across the country have joined with public health officials to implement strict measures to halt the spread, from shutting down schools and businesses to asking everyone to isolate themselves as much as possible. But after more than a week of “social distancing,” with the economy on the ropes, President Donald Trump has begun suggesting it’s time to open things back up.
Baltimore Sun | March 24, 2020
Lives are on the line: Science matters in finding coronavirus treatments
All told, more than 100 clinical trials of dozens of potential treatments have already begun in multiple countries. The start of these trials, however, does not mean a treatment is imminent. Caleb Alexander is quoted.
NBC News | March 24, 2020
What are ECMO machines, and why are they so important to treat coronavirus?
ECMO machines are the only thing that can save the life of a severely infected coronavirus patient when ventilators won’t work, said Ge Bai, an associate professor of accounting and health policy and management at Johns Hopkins University.
Orlando Sentinel | March 21, 2020
Is coronavirus pandemic a reality check?
Johns Hopkins University’s professor Gerard Anderson said an uninsured patient ‘could expect to pay at least $500-$1,000 just to get tested for the virus, and a 10-day hospital stay could amount to a bill of at least $75,000.’ The number of uninsured patients, as the Census Bureau reported, was 28.6 million in 2018.
Prothomalo English Op-Ed | March 19, 2020
Trump taps anti-malarial drug for coronavirus fight
President Trump directed the Food and Drug Administration to repurpose an anti-malarial drug for use against the raging coronavirus pandemic and told states to order badly needed ventilators instead of relying on him. Gerard Anderson is quoted.
Washington Times | March 19, 2020
4 reasons America needs a new coronavirus crisis insurance program based on Medicare
Borrow Medicare’s medical and billing infrastructure to give everyone in America access to coronavirus diagnosis, treatment and recovery services. Joshua Sharfstein and Gerard Anderson are co-contributors.
USA Today | March 19, 2020
COVID-19 testing questions: Experts wonder if Congressional response will help small businesses, employees
Many shopkeepers will want to keep his or her business open if they don’t have the funds to keep an office closed for 14 days. Gerard Anderson is quoted.
CNBC News | March 12, 2020
Coronavirus could financially cripple many Americans
Americans’ health may not be the only thing at stake as the coronavirus continue its unrelenting spread in the U.S. The virus could also prove financially crippling for many individuals. Gerard Anderson is quoted.
CNBC | March 10, 2020
U.S. health system is showing why it's not ready for a coronavirus pandemic
The growing coronavirus outbreak in the United States revealing serious gaps in the health system’s ability to respond to a major epidemic, forcing hospitals and doctors to improvise emergency plans daily, even as they remain uncertain how bad the crisis will get. Gerard Anderson is quoted.
The Washington Post | March 4, 2020
Drug Pricing Related:
Harford residents invited to share stories about rising prescription medication costs at listening session Monday
The Prescription Drug Affordability Board, which was established by the legislature in 2019, is beginning its work by reviewing drug costs in the state and hearing public concerns about the affordability of medications. Gerard Anderson is listed.
Baltimore Sun | October 28, 2020
Trump turns attention to health care with executive orders he says will lower drug prices
Pharmaceutical industry executives are expected at the White House Tuesday. Trump says he’ll sit down with them to talk drug prices, after signing several executive orders which the White House says will help bring those prices down. Gerard Anderson is quoted.
Marketplace | July 27, 2020
Letter: Importing Canadian drugs will only add to the problem
Agree or disagree with an idea of importing prescription drugs from Canada? Gerard Anderson is quoted.
Telegram.com | January 31, 2020
Drugs getting FDA's OK faster, but is that good?
New drugs are being approved by the U.S. Food and Drug Administration for patients based on less and less solid evidence, thanks to incentive programs that have been created to promote drug development, a new study shows. Joshua Sharfstein is quoted.
WebMD | January 14, 2020
Rising cost of prescription drugs in the U.S.
The cost of prescription drugs for all kinds of medications is taking a heavy toll on the average American’s wallet, and officials appear divided on how to stop them from rising. Gerard Anderson is quoted.
WPMT FOX43 News | January 13, 2020
Prescription Drug Affordability Panel gets to work
Members of a new prescription drug panel pledged to do a deep dive into the factors that cause consumers to experience sticker shock at the pharmacy counter. Gerard Anderson is quoted.
Maryland Matters | January 13, 2020
Prescription drug costs driven by manufacturer price hikes, not innovation
The skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently claim, a new study shows. Gerard Anderson is quoted.
NPR | January 7, 2020
2019 Media Mentions
- With encouragement from Trump, states move forward on importing drugs
The Trump administration Wednesday announced plans that would pave the way for Americans to begin purchasing lower priced prescription drugs imported from Canada. Gerard Anderson is quoted.
PEW Trusts | December 18, 2019
- House to vote on Speaker Pelosi's prescription drug bill this week
The House of Representatives is scheduled to vote this week on H.R. 3, Nancy Pelosi’s sweeping new bill looking to lower drug prices. Gerard Anderson is quoted.
Marketplace | December 9, 2019
- Pelosi drug-pricing bill would cost $1 trillion annually for a decade, White House says
House Speaker Nancy Pelosi's signature drug pricing bill would cost the U.S. economy $1 trillion every year for a decade and result in as many as 100 fewer drugs coming to the market over that time, the White House's Council of Economic Advisers said in a Dec. 3 blog post. Gerard Anderson is quoted.
Becker's Hospital Review | December 4, 2019
- White House claims Speaker Nancy Pelosi's drug-pricing bill would result in 100 fewer drugs over a decade
Democratic House Speaker Nancy Pelosi's sweeping drug-pricing bill would result in as many as 100 fewer drugs hitting the U.S. market over the next decade, the White House claimed in a report Tuesday. Gerard Anderson is quoted.
CNBC | December 3, 2019
- Why Americans pay so much for prescription drugs (video with Dr. Gerard Anderson)
Gerard Anderson, professor of health policy and management at the Johns Hopkins Bloomberg School of Public Health, discusses drug prices in the U.S. He also makes the case for Medicare for All on "Bloomberg Markets." The Bloomberg School of Public Health is supported by Michael R. Bloomberg, founder and majority owner of Bloomberg LP, the parent company of Bloomberg News. Gerard Anderson is presented via video.
Bloomberg | November 26, 2019
- How a billionaire couple greased the skids for Nancy Pelosi's drug pricing bill
When House Democrats pass legislation next month that would slash prescription drug spending to the tune of $1 trillion, they'll have John and Laura Arnold to thank. Gerard Anderson is featured.
Stat | November 26, 2019
- Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
All brand-name drugmakers could collectively lose more than $1 trillion and the pharmaceutical industry would still be the most profitable sector, according to an analysis published Nov. 14 by West Health Policy Center and Johns Hopkins Bloomberg School of Public Health in Baltimore. Jeromie Ballreich is quoted.
Becker's Hospital Review | November 14, 2019
- A political race to the bottom on drug prices
President Trump wants the U.S. to pay less than other countries for some prescription drugs covered by Medicare — a benchmark even lower than what congressional Democrats want. Gerard Anderson is quoted.
Axios | November 14, 2019
- New analysis finds large drugmakers could lose $1 trillion in sales and still be the most profitable industry
A new analysis of publicly reported financial data by researchers at West Health Policy Center and Johns Hopkins Bloomberg School of Public Health finds that large, brand-name drug manufacturers would still be the most profitable industry sector even with $1 trillion in lower sales, all while maintaining current research investments. Jeromie Ballreich is quoted.
PR Newswire | November 13, 2019
- It's tiny biotechs -- not big drug makers -- that fear 'nuclear winter' from Pelosi's drug pricing bill
No one asked Paul Hastings what he thinks about Speaker Nancy Pelosi’s major new drug pricing legislation, or how it might affect his company, Nkarta Therapeutics. No one asked Bassil Dahiyat, the CEO of Xencor, or Dr. Barbara Weber, who helms Tango Therapeutics, either. Gerard Anderson is featured.
Stat News | November 12, 2019
- Why are US drug prices so high? It's complicated
One idea to help US consumers facing high prescription drug prices? Import drugs from Canada, where prices are far lower on lifesaving medications. Gerard Anderson is quoted.
Newsday | November 3, 2019
- House Democrats, Republicans spar over bill to lower drug prices
Having HHS secretary negotiate prices a flash point at a House Energy and Commerce Health Subcommittee hearing. Gerard Anderson is quoted.
MedPage Today | September 26, 2019
- Democrats avoid infighting during drug pricing panel on Pelosi bill
Democrats avoided infighting during a hearing on prescription drug prices Wednesday, a positive sign for the passage of a bill recently introduced by House Speaker Nancy Pelosi. Members of the Energy and Commerce subcommittee heard testimony from Gerard Anderson, among others.
Washington Examiner | September 25, 2019
- House Speaker Pelosi unveils Democrats' broad plan to lower prices on the most expensive drugs
House Speaker Nancy Pelosi unveiled a sweeping plan to lower the price of prescription drugs. She and fellow House Democratic leaders have been working for months on a plan to reduce US drug prices. Gerard Anderson is quoted.
CNBC | September 19, 2019
- With ominous TV spots and a senior "strike force," AARP launches an all-out attack on pharma
A multimillion-dollar campaign against the pharmaceutical industry and its high prices is not coming from hospitals or Democratic presidential candidates. Instead, the push is from AARP, the seniors organization better known for travel deals and discount car insurance. Gerard Anderson is quoted.
STAT News | September 17, 2019
- Erie's Congressman wants to make generic insulin a reality
The bill is H.R. 4244, the Market Access for Generic Insulin Competition, or the M.A.G.I.C. Act of 2019. In its simplest form, the bill would clear the way for a synthetic, generic version of insulin to be developed and approved through the abbreviated drug-approval process at the Food and Drug Administration. Jeremy Greene is quoted.
GoErie | September 15, 2019
- Insurers, hospitals could reap benefits from leaked drug price bill from Nancy Pelosi
A leaked summary of a proposed bill from House Speaker Nancy Pelosi to combat drug prices brought some good news for insurers and hospitals struggling with exorbitant drug costs, experts say. Gerard Anderson is quoted.
Fierce Healthcare | September 10, 2019
- Reining in the spending on drugs: What Mass. can learn from other states
Drug prices, long a concern, are drawing new scrutiny now with the advent of cutting-edge medicines that can be life-changing — but that come with eye-popping price tags. Gerard Anderson is quoted.
Boston Globe | August 27, 2019
- Federal court strikes down Trump rule on drug prices in TV ads
The Trump administration’s plans to promote transparency in drug pricing suffered a significant, if not entirely unexpected, legal setback July 9 when the US District Court for the District of Columbia struck down a rule requiring drug makers to disclose the list price for the standard monthly dose of a given drug in any DTC advertising. Ge Bai is quoted.
The Heartland Institute | August 20, 2019
- Just 3% of charity patient assistance programs accept uninsured patients
Only 3% of charity patient assistance programs accept patients without insurance, according to a study recently published in JAMA. So-Yeon Kang is quoted.
Healio | August 16, 2019
- Help how? Patient charities favor the insured and more expensive brand-name drugs
Amid rising scrutiny of the ties between patient charities and drug makers, a new study finds that nearly all of the programs run by the six largest organizations failed to provide assistance to people without insurance and were also more likely to cover expensive brand-name medicines than generics. Gerard Anderson is quoted.
Stat News | August 6, 2019
- Drug assistance programs offer little charity to uninsured
Many patients who receive assistance from charities set up to defray prescription drugs costs may already have insurance that covers most the cost for their medications, a U.S. study suggests. Gerard Anderson is quoted.
Reuters | August 6, 2019
- Trump reverses policy of importing drugs in bid to lower prices: HHS offers two pathways, in notable evolution
The Trump administration opened the door Wednesday to allowing Americans to import drugs from Canada and other foreign markets, reversing long-standing U.S. policy as President Trump searches for ways to make good on his campaign promise to bring down prices. Gerard Anderson is quoted.
The Washington Times | July 31, 2019
- Trump admin opens door to allow drug importation from Canada
The Trump administration took hesitant first steps Wednesday to allow the importation of certain drugs from Canada and other countries. Gerard Anderson is quoted.
NBC2 News | July 31, 2019
- Understanding the Senate Finance Committee's drug pricing package
This week, the Senate Finance Committee released its long-awaited drug pricing package and held a markup on the subject, advancing the package to the floor. Composed in a bipartisan fashion by Chairman Chuck Grassley and Ranking Member Ron Wyden, the package if enacted would go farther than any other drug pricing reform in decades, even as it leaves unanswered several large issues. Gerard Anderson is quoted.
Health Affairs | July 26, 2019
- Senate Finance Committee to consider drug costs
Drug prices just keep rising – at five times the rate of inflation. the bipartisan measure would add an out-of -pocket maximum for Medicare beneficiaries and force companies to pay money back if their prices rise above inflation. Gerard Anderson is quoted.
Marketplace | July 25, 2019
- Summer setbacks: The long road to lower drug prices hits some potholes
Now it’s July, and whether it’s the humidity or the lobbyists, Washington — and the prospects for substantial change — look hazy. Two of the Trump administration’s primary targets, slashing rebates to drug supply middlemen and requiring prices in drug ads, fell apart in recent weeks. Gerard Anderson is quoted.
Kaiser Health News | July 24, 2019
- Surprise billing, drug prices help drive health lobbying boost
Hospital and doctors’ groups are on pace to spend millions more dollars this year on lobbying than last year as Congress considers various hot-button health care issues, like surprise medical bills and drug pricing. Ge Bai is quoted.
Bloomberg Government | July 23, 2019
- Trump 'favored-nation' drug pricing order could hammer profits
President Trump is potentially seeking to require that drugmakers sell medicine in the U.S. at the lowest cost offered elsewhere in the world, a move that would have a radical effect on the industry and deepen the dispute between pharmaceutical firms and the administration over rising treatment prices. Gerard Anderson is quoted.
Yahoo Finance | July 8, 2019
- New rule requires drug companies to state prices in ads
America’s $450 billion-a-year drug industry is about to get a new wrinkle as a rule finalized in May by the U.S. Department of Health and Human Services (HHS) requires all pharmaceutical companies to include the list prices of their drugs. Ge Bai is quoted.
The Heartland Institute | June 28, 2019
- Striking a balance: Drug prices, profits and incentives for innovation
America’s $450 billion-a-year drug industry is about to get a new wrinkle as a rule finalized in May by the U.S. Department of Health and Human Services (HHS) requires all pharmaceutical companies to include the list prices of their drugs. Gerard Anderson is quoted.
Brookings | June 4, 2019
- 'Substantial' price increases continue for most popular brand-name drugs
Costs for the 49 top-selling brand-name prescription drugs in the United States increased by a median 76% between 2012 and 2017, with all but one drug displaying regular annual or biannual price increases. Jeromie Ballreich is featured.
Healio | May 31, 2019
- Will including prescription drug prices in ads drive down prices?
A new rule will soon require most drug ads found on TV to state the drug's list price. Here is what science says about how people will likely react. Ge Bai is featured.
Pacific Standard | May 15, 2019
- Most of the profit in the health-care industry is going to drug companies -- here's why you should care
Why pharmaceutical manufacturers' sky-high profits matter for consumers. Ge Bai is quoted.
MarketWatch | May 13, 2019
- Monday morning politics; 10 minute explainer: Pharmacy benefits managers
Compred to some other countries, the US pays three to four times more for drugs, according to a new study. Gerard Anderson is quoted.
WNYC / Published by The Brian Lehrer Show | May 13, 2019
- The future of referencing pricing in the US
Gerard Anderson explains the role of Pharmacy Benefits Managers and whether they are to blame for the rising costs of prescriptions, as pharmaceutical companies and politicians are claiming.
Managed Healthcare Executive | May 12, 2019
- Report shows US brand-name drug prices "highest in the world"
A new study has found that prices for brand-name prescription drugs averaged 3.2 to 4.1 times higher in the US compared with other countries. Gerard Anderson is quoted.
European Pharmaceutical Review | May 7, 2019
- External referral drug pricing could economize Medicare tens of billions
The study discovered that the more time brand name prescription drug was on the market, the more pronounced the price discrepancy. Gerard Anderson is quoted.
World Capital News | May 7, 2019
- Should the U.S. save Medicare money by pegging drug prices to what other countries pay?
If the US wants a better deal on some medicines, the federal government could try pegging prices to what is paid by Japan, the UK, and the Canadian province of Ontario. Gerard Anderson is quoted.
Stat News | May 7, 2019
- Medicaid managed care programs' contracts for generic drugs are inefficient
This article will describe inefficiencies in Medicaid managed care programs' contracting with pharmacy benefit managers (PBMs) for generic drugs and will explain the root cause of the inefficiencies and discuss an alternative PBM contracting model for generic drugs in state Medicaid managed care programs. Ge Bai and Mariana Socal are authors of this article and are featured.
Health Affairs | May 1, 2019
- First quarter drug lobbying outpaces other health care sectors
Big spending comes amid bipartisan support for legislation to lower drug prices. Gerard Anderson is quoted.
Roll Call | April 24, 2019
- Behind the scenes, three key figures help shape the Democrats' strategy on reducing drug prices
A closer look at Richard Frank, Lauren Aronson and Gerard Anderson -- three of the key figures and Democratic health-policy thought leaders working closely with Wendell Primus, a top advisor for House Speaker Nancy Pelosi. Gerard Anderson is referenced.
Kaiser Health News | April 16, 2019
- Democrats feud over drug pricing policy, as progressives push pragmatists to be bolder
Democratic leadership and the party's progressive flank are feuding over how best to lower drug prices. Gerard Anderson is quoted.
Stat News | April 15, 2019
- Jim Jordan, Mark Meadows warn Big Pharma execs not to cooperate with drug-price probe
Leading members of the House Freedom Caucus take Big Pharma's side in Oversight Committee probe of drug prices. Gerard Anderson is quoted.
Salon | April 10, 2019
- Gov. Tony Evers wants prescription drug companies and other entities to disclose information on prices
Like most prices in health care, what health plans pay for prescription drugs is cloaked in secrecy. Governor Tony Evers wants those prices to be at least a bit less secret. Gerard Anderson is quoted.
Journal Sentinel | April 9, 2019
- Democratic takeover of House sparks drug-price legislation talks
Strong legislation unlikely given patient and industry opposition. Gerard Anderson is mentioned.
P&T Community | April 1, 2019
- 'Stop Rx Greed' campaign calls on Washington to cut drug prices
The AARP is calling on its powerhouse of 37.8 million members to tell the powers that be in Washington DC that it's time to do something about rising drug costs. Gerard Anderson is quoted.
Forbes | March 13, 2019
- VitalWare hospital chargemaster brings analysis to coding, billing process
A hospital chargemaster is helping two health systems identify and address billing and coding inaccuracies. Ge Bai is featured.
TechTarget | March 12, 2019
- Editorial: High drug prices just one example of special interests thwarting popular will
Research and development accounts for only 17 percent of total spending at most big pharma companies. Gerard Anderson is quoted.
Valley News | March 12, 2019
- Two Maryland bills are the state's latest attempt to rein in drug prices
Even as Congress holds hearings and the White House proposes updating rules for drug pricing, Maryland and some other states are also searching for ways to make prescription medications more affordable. Gerard Anderson is featured.
The Washington Post | March 5, 2019
- States, eager to lower drug prices, regroup after courts strike down Maryland 'price-gouging' law
A legal setback in Maryland has state legislatures across the country re-examining their efforts to lower drug prices, with lawyers from Nevada to Illinois combing through bills to ensure they can withstand future challenges from pharmaceutical industry groups. Gerard Anderson is quoted.
Stat | March 1, 2019
- U.S. patient advocacy groups received majority of pharma donations in multi-country study
A new study by Johns Hopkins Bloomberg School of Public Health researchers found that U.S.-based patient advocacy organizations received a disproportionate amount of contributions made by the world's 10 largest pharmaceutical companies in 2016. Gerard Anderson and So-Yeon Kang are featured.
Global Health News Wire | February 25, 2019
- Congress starts to go after big pharma
Congress on Tuesday jumped into its first round of hearings on drug prices for the year, vowing to take action on a problem that the president and the public see as a top concern for the country. Gerard Anderson is featured.
Washington Examiner | January 31, 2019
- Dueling drug pricing hearings in House and Senate
Both the House and Senate kick off drug pricing hearings this week, with diabetes patients taking the floor in each. Gerard Anderson is listed.
Politico | January 28, 2019
- Study: Disclosing drug prices might not cut costs
By itself, a Trump administration plan to make drug companies disclose the cost of their medicines in TV ads is unlikely to help tame drug prices, a new study shows. Ge Bai is quoted.
WebMD | January 25, 2019
- Opinion: Our dysfunctional government should at least be able to lower drug prices
Commentary by a former US Senator from Delaware outlines drug pricing and how best to lower the costs. Gerard Anderson is quoted.
Delaware Online | January 25, 2019
- Drug ad price transparency plan contains huge loophole, researchers say
The Trump administration's proposal to require pharmaceutical companies to list drug prices in television ads would have a profound impact on the way consumers think about expensive drugs and whether they would ask their doctor about them, according to a study published this week. Ge Bai, study co-author is quoted.
CNN Wire | January 22, 2019
- Secretive "rebate trap" keeps generic drugs for diabetes and other ills out of reach
In a practice that policy experts say smothers competition and keeps prices high, drug companies routinely make hidden pacts with middlemen that effectively block patients from getting cheaper generic medicines. Lead author Gerard Anderson is quoted.
ABC News | January 19, 2019
- FDA directs dwindling resources toward reviewing new drugs
The Food and Drug Administration plans to furlough more people and suspend lower-priority tasks to preserve money for drug reviews, including for new treatments for depression, diabetes and several types of cancer. Joshua Sharfstein is quoted.
The Washington Post | January 17, 2019
- Here's why many prescription drugs in the US cost so much -- and it's not innovation or improvement
Americans spend about $1,200 on prescriptions drugs a year, according to the latest figures from the Organization for Economic Cooperation and Development. That's more than people pay in any other developed country in the world. Gerard Anderson is quoted.
CNBC | January 14, 2019
- New study shows Americans pay the most for health care while getting the least care for it
As the old adage goes, you get what you pay for. Unless you’re an American in need of healthcare. Then you pay somewhere around double for about the same quality care. Lead author Gerard Anderson is quoted.
Good | January 11, 2019
- US spends twice as much on health care as its peers
Americans spend more than twice as much on health care per person as their peers in developed nations. The study was conducted by the Johns Hopkins Bloomberg School of Public Health. Lead author Gerard Anderson is quoted.
CNN | January 8, 2019
- Hospitals must now post their prices online: $7 for 5-cent aspirin?
Hoping to empower consumers who are shouldering more and more of their health care costs each year, the federal government this year is requiring hospitals across the country to post their standard price lists on their websites. Gerard Anderson is quoted.
The Mercury News | January 6, 2019
2018 Media Mentions
- How Sen. Orrin Hatch shaped America's health care in controversial ways
Though his politics are right of center and he lobbied hard against the Affordable Care Act, Republican Sen. Orrin Hatch also has been key to passing several landmark health laws with bipartisan support. Jeremy Greene is quoted.
National Public Radio | December 31, 2018
- Naloxone maker rolls out cheaper generic, after pricing outcry
The overdose-reversal drug is a critical tool to easing America’s coast-to-coast opioid epidemic. But not everyone on the front lines has all they need. Baltimore’s health department is rationing its supplies of naloxone because it says it can’t afford an adequate stockpile. Gerard Anderson is quoted.
The Washington Times | December 12, 2018
- Price slashed for Trump Medicare, cancer, HIV, and depression not covered
The latest change to occur in Trump Medicare is a price slash for pharmacy bought drugs and exclusion of coverage for specific ‘protected’ categories of drugs used in treatment of cancer, depression and HIV. Gerard Anderson is mentioned.
Business Industry News | December 9, 2018
- The amount Americans spend on healthcare is still growing, but more and more slowly
The amount of money spent on healthcare in America is still growing, but at a slower rate than recent years, according to the U.S. government’s annual account. Gerard Anderson is quoted.
Forbes | December 6, 2018
- Trump Medicare plan promises lower prescription prices for seniors, but also risks losing coverage ...
The Trump administration is making good on its latest effort to lower out-of-pocket drug costs for Medicare recipients, but its approach could also limit drug options or even risk eliminating coverage of some prescriptions. Gerard Anderson is featured.
CNBC | November 27, 2018
- Playing on feat and fun, hospitals follow pharma in direct-to-consumer advertising
Hospitals are using TV spots like this one to attract lucrative patients into their hospitals as health care costs and industry competition escalate. Gerard Anderson is quoted.
Kaiser Health News | November 19, 2018
- Could free healthcare for all ever be a reality in the US?
Healthcare was a big driver in the outcome of the recent US mid-term elections. But could the Democrats' vision of a truly reformed healthcare system ever become a reality? Gerard Anderson is quoted.
Public Finance International | November 13, 2018
- Quick: What's the difference between Medicare-for-all and single-payer?
Across the country, catchphrases such as “Medicare-for-all,” “single-payer,” “public option” and “universal health care” are sweeping state and federal political races as Democrats tap into voter anger about GOP efforts to kill the Affordable Care Act and erode protections for people with preexisting conditions. Gerard Anderson is quoted.
California Healthline | November 2, 2018
- Q&A: Medicare-for-all is getting a shot of attention. But what does it really mean?
Medicare-for-all is now drawing a surprising amount of attention and support. The bill would create a single national health insurance program that would replace the country’s hodgepodge system in which people get health insurance through employers, Medicare, Medicaid or the Children’s Health Insurance Program, or buy it privately. Gerard Anderson is featured.
Journal Sentinel (USA Today Network) | October 31, 2018
- Trump says new proposal will lower some USA drug prices
In a speech Thursday at the Department of Health and Human Services, Trump said his administration would be taking the "revolutionary" move of allowing Medicare to directly negotiate prices with drug companies, which he says have "rigged" the system, causing USA patients to pay more for their medicines. Gerard Anderson is featured.
Click Lancashire Independent News | October 29, 2018
- Why Trump’s Medicare Plan Won’t Cut Prices Anytime Soon
President Trump’s newly unveiled test plan to lower Medicare Part B drug costs may have limited resonance in the days before the midterm elections — and could face a difficult, if not impossible, road over the longer-term as well, given resistance from the pharmaceutical industry and doctors as well as some conservatives worried that the plan runs counter to their free-market principles and some Democrats who say the plan doesn’t go far enough.. Gerard Anderson is quoted.
The Fiscal Times | October 26, 2018
- Pharmaceutical industry challenges Trump plan forcing companies to reveal drug prices in TV ads
The Trump administration is proposing that companies be required to disclose the cost of drugs in legible print on all video advertisements. The pharmaceutical industry is fighting back, arguing that consumers should be able to find the price elsewhere and that few people end up paying the list price anyway. Gerard Anderson is quoted.
Washington Times | October 24, 2018
- Millennials dropping primary care physicians in exchange for expedited and less expensive alternatives: Convenience and price transparency are driving the switch
Millennials seem to like what they see in drugstore-based clinics and urgent care centers that can cater to their needs when they need it. Gerard Anderson is quoted.
Consumer Affairs | October 9, 2018
- Behind your rising health-care bills: Secret hospital deals that squelch competition
Contracts with insurers allow hospitals to hide prices from consumers, add fees and discourage use of less-expensive rivals. Gerard Anderson is quoted.
Wall Street Journal | September 18, 2018
- Here’s what it costs to give birth in 18 places around the world
The United States has one of the highest costs, with "surprise billing" skyrocketing some bills to six figures. Gerard Anderson is quoted.
Business Insider | July 20, 2018
- What Pfizer, Trump, and consumers got out of a surprising deal -- and what they didn't
After months of pledging he would get pharmaceutical companies to lower their prices, President Trump can now say that he pressed the CEO of a major drug maker, Phizer, to back down on a series of price hikes. However, none of it might make any difference in the amount they pay for their prescription drugs, analysts say. Pfizer's prices will likely go right back up at the end of the year. Gerard Anderson is quoted.
Stat News | July 11, 2018
- Address regulatory burdens, antikickback laws to lower healthcare cost
The skyrocketing cost of healthcare is a result of a system working as intended -- to "extract resources from" the people using it, experts say. Because patients have limited ability to navigate the system, they have limited power to negotiate or push for change in the cost of care. Gerard Anderson is featured.
Fierce Healthcare | July 2, 2018
- Failed Bush-era drug-pricing program may make more sense under Trump
A failed Bush-era program aimed at curbing the cost of doctor-administered drugs might actually work if the Trump administration has the political will to revive it, a number of independent drug experts agree. The Competitive Acquisition Program, which allows third parties to negotiate with manufacturers for drugs that physicians then buy, was among the ideas included in President Trump's blueprint on lowering drug prices. Gerard Anderson is quoted.
Politico | May 29, 2018
- Trump rolls out drug price plan but it's still a work in progress
Many of the policies the government listed in its 44-page "American Patients First" plan are either modest steps the administration has already taken, or policies that it has identified as needing further time and study. Gerard Anderson is quoted.
Politico | May 11, 2018
- California considers medical price control
Proponents of medical price controls in California argue that government intervention is necessary to counter the anti-competitive market power of key providers. Gerard Anderson is quoted.
New York Magazine | April 21, 2018
- A Maryland law to prevent ‘unconscionable’ price hikes on old drugs has been struck down
A Maryland law crafted to deter companies from instituting large price increases on old, off-patent drugs was struck down by a federal appeals court Friday, in a decision that could give pause to other states considering similar legislation. Gerard Anderson is quoted.
Washington Post | April 13, 2018
- Bill of the month: A tale of 2 CT scanners — one richer, one poorer
Benjamin Hynden, a financial adviser in Fort Myers, Fla, got two cat scans, one at an imaging center, the other in a hospital ER. The first bill was $298. The second, from the hospital, was $10,174.75. The segment unpacks the price difference. Gerard Anderson is quoted.
- Sewage and water leaks in hospital operating rooms cited in lawsuit over patient’s death
Persistent water and sewage leaks in and around the operating rooms of Washington’s largest hospital are at the center of a lawsuit seeking millions in damages in the infection-related death of a retired Northern Virginia schoolteacher. Gerard Anderson is quoted.
Washington Post | April 2, 2018
- Trump’s drug-price crackdown misses the mark, experts say
Experts and advocacy groups say policies in the administration’s latest budget proposal don’t tackle the biggest driver of high prices: Nothing prevents a drugmaker from setting a price at whatever level it wants. Gerard Anderson is quoted.
Washington Examiner | March 13, 2018
- Cigna to buy Rx manager for $67B
In another mega deal to reshape the business of negotiating drug prices, health insurer Cigna said Thursday that it will acquire Express Scripts Holding, the nation’s largest pharmacy benefit manager, in a package valued at $67 billion. Gerard Anderson is quoted.
Northwest Arkansas Online | March 9, 2018
- Daily on healthcare: Trump gives a nod to Obamacare insurer payments
Professor Gerard Anderson is quoted in this article about Obamacare insurer payments. An interesting addition to President Trump’s budget is a call for insurers to get cost-sharing reduction payments and risk corridor payments, which many conservatives have attacked as a “bailout” for insurance companies.
Washington Examiner | February 13, 2018
- Trump budget’s reforms unlikely to make big dent in high drug prices, experts say
President Trump’s budget request contains several proposals to lower drug prices, but experts say they won’t help much since they aren’t targeting the priciest, brand-name products. Gerard Anderson is quoted in the article.
Washington Examiner | February 12, 2018
- Big Pharma is thriving off the flu
As more Americans get sick, the economy stands to lose more than $10 billion. Professor Gerard Anderson explains how nearly $2 billion may be trickling into the pockets of vaccine and medication makers and distributors, pharmacies, and health care providers.
Daily Mail | February 12, 2018
- Hospitals made $21B on Wall Street last year, but are patients seeing those profits?
The booming stock market has been good for ordinary Americans with retirement accounts, and it also has enriched another class of investors to an extent some find problematic: Some medical economists say that nonprofit hospitals are using lucrative Wall Street portfolios to fatten their bottom lines rather than lower what patients pay for health care.
NBC News | February 12, 2018
- Reducing healthcare costs doesn’t require Bezos/Buffet/Dimon magic: Every other country already knows how
Bezos, Buffett and Dimon didn’t even have to look beyond the U.S. boundaries to find clues to how to reduce healthcare costs — they merely had to look at America’s public healthcare programs such as Medicare, Medicaid and CHIP. All place limits on reimbursements to doctors and hospitals, some more stringent than others.
LA Times | January 31, 2018
- Another sticking point in Highmark-UPMC break up: Emergency care costs
Picture for a moment this unsettling scenario: Some time after June 30, 2019, when Highmark and UPMC have finally gone their separate ways, a Highmark-insured pedestrian is seriously injured and unconscious after being struck by a car while crossing Fifth Avenue in Oakland. Gerard Anderson is quoted.
Pittsburgh Post-Gazette | January 21, 2018
- Pharma, under attack for drug prices, started an industry war
With national and state advertising campaigns, white papers and cartoon infographics, the powerful and well-funded drug industry lobby spent 2017 working to redirect public anger about drug prices to pharmacy benefits managers (or PBMs): links in the supply chain that sits invisibly between the patient and the drug maker.
Washington Post | January 2, 2018
2017 Media Mentions
- Lawmakers zero in on next target in fight against high drug prices
Both Republican and Democratic senators have criticized moves by drug makers to extend the life of their monopolies on sales. But action on high drug prices, a major concern for consumers, has been so far negligible in this Congress. Gerard Anderson is quoted.
Washington Examiner | December 18, 2017
- CVS-Aetna merger aims to transform healthcare
If completed, the deal would combine one of America’s largest drugstore retailers with a health benefits provider, giving the combined companies’ additional leverage in negotiating drug prices from pharmaceutical companies. Gerard Anderson is quoted.
Consumer Affairs | December 7, 2017
- At drug hearing, senators discuss meanings of price and value – and debate health reform
Most of the extra $933 billion Americans spent on health care in 2013 versus 1996 is due to higher charges for care and patients getting more intense, expensive care. Gerard Anderson is quoted.
Forbes | November 16, 2017
- D.C. public hospital’s report on patient death omitted key details
Officials at the District’s only public hospital failed to report to regulators key details about the death of a patient in the facility’s nursing home in August, an incident report submitted to the D.C. Department of Health shows. Gerard Anderson is quoted.
Washington Post | November 6, 2017
- Ohio Issue 2 ballot initiative proponents overstate impact on EpiPen prices
Issue 2, a ballot initiative that would require drugs prices be transparent to consumers, is aimed at lowering health care costs. However, an EpiPen ad has misinterpreted the population that Issue 2 benefits, as approximately 70 percent of EpiPen users are privately insured, and Medicaid patients already pay nothing out of pocket.
Politifact | October 16, 2017
- California governor signs law to make drug pricing more transparent
California Governor Jerry Brown defied the drug industry Monday when he signed the most comprehensive drug price transparency bill in the nation. This bill will force drug makers to publicly justify big price hikes. Gerard Anderson is quoted in this article.
NPR | October 12, 2017
- California bill would compel drugmakers to justify price hikes
Gov. Jerry Brown is scheduled to sign a bill that would force pharmaceutical companies to justify big price hikes on drugs in California. The bill would require drug companies to give California 60 days’ notice anytime they plan to raise the price of a drug by 16 percent or more over two years.
NPR | October 6, 2017
- Dr. Gerard Anderson discusses barriers to accessing medications
Gerard Anderson is featured in this article. Accessibility to affordable medications have been increasingly limited due to rising drug prices. Dr. Anderson suggests that the remedy to this issue is editing the pricing algorithms in place.
The American Journal of Managed Care | September 8, 2017
- What the Carolinas HealthCare megadeal means for patients, employees – and Charlotte
Carolinas HealthCare System and UNC Health Care have teamed up, and their partnerships will bring about vast changes to residents of North Carolina. Health care will be expanded through this effort, and treatments to serious issues such as cancer, mental health, and substance abuse will be upped. Gerard Anderson is quoted.
Charlotte Observer | September 1, 2017
- Here’s how expanding Medicare could set us on the path to universal health coverage
The legislative impasse over health-care reform has given rise to the idea of single-payers. The road from here to there is uncertain, but several routes are being weighed. Gerard Anderson's research is mentioned.
LA Times | August 21, 2017
- Why the world should pay attention to America’s civil war over healthcare
The proposed changes to the U.S. healthcare system defy comparison to the limited privatization that exists in Britain, for example. The “social fabric,” Gerard Anderson states, is very different between the U.S. and Britain, and this exposes “a lack of social solidarity.” Gerard Anderson provides further insight.
The Guardian | June 30, 2017
- Trump administration signals initial steps to deal with drug prices
The noted effort by the Trump administration would likely have a limited impact, affecting prices of older drugs whose patents and exclusivity have expired and lack competitors. In contrast, the major driver of drug spending growth in 2016 was new brands that had been on the market for less than 2 years.
Washington Post | June 26, 2017